Paul Richardson, MD, Clinical Program Leader, Director of Clinical Research, Jerome Lipper Multiple Myeloma, Institute Physician, Harvard Medical School considers whether isatuximab can remain a treatment option for relapsed/refractory multiple myeloma (MM).
Isatuximab as a Treatment Option for MM
